Sanofi Articles
News briefs from Merck KGaA and Sanofi
5 July 2012
European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada
26 June 2012
Batch of mixed opinions from FDA advisory panels
21 June 2012
More news from American Diabetes Association meeting
13 June 2012
Highlights of American Diabetes Association meeting
11 June 2012
Sanofi's strong 1st-qtr driven by Genzyme
27 April 2012
Genzyme and Isis file Kynamro NDA in USA
2 April 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
US consumer groups call on FTC to investigate anti-competitive practices of vaccine makers
21 March 2012
Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers
20 March 2012
Sanofi expands in biosurgery, buying Pluromed
18 March 2012
Senior appointments as Sanofi and Onyx
5 March 2012
B-MS ties knot with Duke University on R&D
29 February 2012
Sanofi considers expanding in Ukraine pharma market
24 February 2012
Sanofi surprises Osiris by pulling out of Prochymal deal
13 February 2012
$20 million lixisenatide milestone for Zealand Pharma
13 February 2012
Positive Ph II results for Genzyme’s oral Gaucher drug
9 February 2012
Clopidogrel with aspirin does not prevent more small strokes
5 February 2012
Watson settles over Exalgo; gets favorable news on enoxaparin
29 January 2012
Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG
25 January 2012
Genzyme Framingham plant now cleared by US and EU regulators
24 January 2012
Sanofi Pasteur and Vivalis extend MAb accord
19 January 2012
Zytiga overtaking Provenge in MCRPC
17 January 2012
Negative NICE guidance for Sanofi prostate cancer drug
12 January 2012
Three new partnerships for Sanofi
10 January 2012
Zacks analysts retain neutral stance on Sanofi
5 January 2012
Exelixis and Sanofi terminate $1 billion cancer deal
23 December 2011
FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints
20 December 2011
Isis sees Kynamro delay; adds new drugs to pipeline
15 December 2011
China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015
22 November 2011
Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases
16 November 2011
Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif
15 November 2011
Preliminary results for Sanofi and Regeneron anti-PCSK9 antibody show dramatic decrease in “bad” cholesterol
14 November 2011
EU Pharma re-rating stalled against EU market vis-a-vis defensives, says Nomura analyst
13 November 2011
Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma
4 November 2011
Sanofi to top Pfizer as number one for global pharma sales
1 November 2011
Oxford BioMedica in glaucoma R&D accord with Mayo Clinic
31 October 2011
Sanofi names David Meeker as chief executive of Genzyme; Exelixis hires former Genentech exec
25 October 2011
As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst
24 October 2011
Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif
24 October 2011
Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing
21 October 2011
Watson temporarily restrained from marketing generic Lovenox; challenges Pfizer’s Embeda patent
10 October 2011
Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant
7 October 2011
UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen
30 September 2011
EMA recommends restricting use of Sanofi AF drug Multaq, but sees positive benefit-risk in some patients
23 September 2011
Sanofi prevails over Sun Pharma in Eloxatin patent suit; another generic Lovenox approved
20 September 2011
Ongoing supply problems for Genzyme’s Cerezyme
19 September 2011
Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting
13 September 2011
PTC Therapeutics and Genzyme restructuring ataluren collaboration
4 September 2011
Pfizer in generic Lipitor deals with Sanofi and Dr Reddy’s
1 September 2011
Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv
1 September 2011
Speculation Takeda is looking to buy India’s Cipla or Lupin; Sanofi acquires OTC firm
25 August 2011
US FDA now joins in probe of Sanofi’s Multaq safety
25 July 2011
Brazil patent office scores victory over Multaq case
13 July 2011
Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq
12 July 2011
CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns
8 July 2011
Merck Serono strengthens executive team; ProStrakan names new CEO; Sanofi Pasteur MSD gets new president
8 July 2011
Pharma’s differentiated strategies for evolving health care landscape presented at Nomura conference
5 July 2011
Sanofi debuts prostate cancer drug Jevtana in UK
5 July 2011
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
